The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Axicabtagene ciloleucel approved by the EC for the treatment of DLBCL and PMBCL
On 27 August 2018, the European Commission (EC) granted a marketing authorization for axicabtagene ciloleucel (Yescarta) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
The European Medicine's Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for axicabtagene ciloleucel (axi-cel) on 29 June 2018. It is a CD19-directed chimeric antigen receptor CAR-T therapy that was granted PRIME status (priority medicines) by the EMA in 2016. Axi-cel was approved by the US Food and Drug Administration (FDA) on October 18 2017.
The marketing authorization means that axi-cel will be able to be prescribed as a treatment, in accordance with the indication, in countries in the European Union and Norway, Iceland and Liechtenstein. The approval follows results from the ZUMA-1 clinical study.
Professor Frederik Locke, H.Lee Moffitt Cancer Center, Tampa, Florida, commented on the duration of response from the study at the annual meeting of the American Society of Clinical Oncology in Chicago, June 2018. "What we found was that for patients in a partial response or complete response, at three months after a single infusion of CAR-T therapy, 80% of those patients remained in remission one year after the therapy was given." He added that "many of those responses deepened over time."
References